Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
about
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerUse of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.Estimating the potential annual welfare impact of innovative drugs in use in Switzerland.Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)What is the role of maintenance therapy in the treatment of non-small cell lung cancer?Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer.Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Government use licenses in Thailand: an assessment of the health and economic impactsCost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapyCost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy.Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysisQuality-of-life concerns in lung cancer patients.Clinical and economic review of erlotinib in non-small-cell lung cancer.A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.Treatment of lung cancer: will financial issues become a criterion of choice?Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
P2860
Q28487847-8086D15E-404D-4511-9974-063EBC264BB1Q31061574-74EC0793-774D-4E88-A303-7C0D37174A99Q33561563-5FBA4EC3-879C-4FE6-9EFB-892CA8BBD222Q33658487-C603FF73-4195-457A-827E-CC95FADA1428Q34112596-030A624E-8E90-40B4-BF27-4ABA5BE6B9EDQ34346373-34ABE671-C440-4EB6-A7F2-04A1E374583DQ34565988-E63B8EBE-DF5B-413E-AC36-5DE83B788111Q34727967-05AD343B-9F84-4922-BB61-BD7B0D1EADD8Q35076269-4BFBC47F-C074-422D-AF6C-54E3C441E1A0Q35109837-3DF05581-BAB3-44FF-9FE9-3E7180CD69DDQ35167535-1433CE63-1CEA-4BAE-B7E4-E4AFB9798BAFQ35222575-1DF54D27-1EAE-45C1-8A3B-5B3BD84C396DQ35844278-C948EF19-1459-4521-9F35-71EA9F44305BQ36212489-CE095F81-3699-4E18-B77C-724F1DBFC8E1Q36765647-97942DEF-07E3-4362-BED4-9CFA66F82A33Q37573653-6BF074D0-2F8A-49FD-9438-D3F100AAE052Q37611801-4508497C-8060-4EDA-9EED-8CDABBE32A98Q37645248-BA71DCF6-7483-499F-8631-6882F788E582Q37820679-3768602F-E515-405D-B3BD-841FD57E10C7Q38042709-C838BBCA-F4E1-423A-B044-4D013FE6C838Q38074876-66C74E8A-E162-415A-BCC4-98D8F6BF2C7EQ38152967-01F80A8A-EEF0-467C-BD6D-A1EC75BCF198Q42371658-56BA4049-896A-4F9A-905E-ECAFBA98ACE2Q45833913-A3EA5215-5667-44B9-8ED3-FFD502C80247Q50238133-EE7D5C68-283D-4B05-B588-DB79F87C80F0Q50632474-38650005-F4A4-45F0-ADA8-AB3599E1BAADQ50892830-DD8E4683-93ED-4A8F-B56C-D6B3045FB873
P2860
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Comparative clinical and econo ...... mall cell lung cancer (NSCLC).
@en
Comparative clinical and econo ...... ory non-small cell lung cancer
@nl
type
label
Comparative clinical and econo ...... mall cell lung cancer (NSCLC).
@en
Comparative clinical and econo ...... ory non-small cell lung cancer
@nl
prefLabel
Comparative clinical and econo ...... mall cell lung cancer (NSCLC).
@en
Comparative clinical and econo ...... ory non-small cell lung cancer
@nl
P2093
P1433
P1476
Comparative clinical and econo ...... mall cell lung cancer (NSCLC).
@en
P2093
Carolina Reyes
David L Veenstra
Deborah Lubeck
Josh J Carlson
Nina Oestreicher
Scott D Ramsey
P304
P356
10.1016/J.LUNGCAN.2007.12.023
P577
2008-03-04T00:00:00Z